Surgical resection after TNFerade™ therapy for locally advanced pancreatic cancer

Journal of the Pancreas

Volumn 10, Issue 5, 2009, Pages 535-538

  Chadha, Manprett K ^a   Litwin, Alan ^a   Levea, Charles ^b   Iyer, Renuka ^a   Yang, Gary ^b   Javle, Milind ^c   Gibbs, John F ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gene Therapy; Neoadjuvant Therapy; Pancreatic Neoplasms; Tumor Necrosis Factor alpha

Indexed keywords

ALKALINE PHOSPHATASE; CA 19-9 ANTIGEN; FLUOROURACIL; GEMCITABINE; TNFERADE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILE DUCT STENT; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EPIGASTRIC PAIN; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LYMPHADENOPATHY; PANCREAS BIOPSY; PANCREAS CANCER; PROTEIN BLOOD LEVEL; STENT; TREATMENT RESPONSE; TUMOR VOLUME; WEIGHT REDUCTION;

ADENOCARCINOMA; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GENE THERAPY; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROMOTER REGIONS, GENETIC; RADIOTHERAPY; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349285008     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009.
2. Chu QD, Khushalani N, Javle MM et al. Should adjuvant therapy remain the standard of care for patients with resected adenocarcinoma of the pancreas? Ann Surg Oncol. 2003 Jun; 10(5):539-545.
3. Evans D B, Wolff R A, Crane C H. Neoadjuvant Strategies for Pancreatic Cancer. Oncology 2001; 15(6):727-747.
4. Hallahan DE, Vokes EE, Rubin SJ, et al: Phase I dose-escalation study of tumor necrosis factor alpha and concomitant radiation therapy. Cancer J Sci Am1995; 1: 204-209.
5. Senzer N, Sridhar M, Alexander R et al: TNFerade Biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors. J Clin Oncol 2004; 22:592-601.
6. Hallahan DE, Mauceri JJ, Seung LP, et al: Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-791.
7. McLoughlin JM, McCarty TM, Cunningham C, Clark V, Senzer N, Nemunaitis J, Kuhn JA. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol. 2005 Oct;12(10):825-830.
8. Murugesan SR, King CR, Osborn R, Fairweather WR, O'Reilly EM, Thornton MO, Wei LL. Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene Ther. 2009 May 15.